Humana (HUM) Stock Forecast & Price Target

Humana is positioned favorably because its 3Q26 results showed better-than-expected medical cost trends, with Insurance segment MLR at 93.7% versus 94.3% consensus and consolidated revenue of $41.2B, while management raised 2026 adjusted EPS guidance to at least $9.50. Its core Medicare Advantage franchise is gaining momentum, with individual MA membership up 23% YTD, group MA margins improving about 500 bps ex-Stars, and 2027 bids priced first for margin, second for retention, and third for growth. The balance sheet is also strengthening as debt-to-capital fell to 40.9%, and the BlackRock JV plus the Gentiva sale should further improve capital flexibility, supporting investments and shareholder returns as earnings recover.

Humana is facing a fundamentally constrained earnings setup because operating efficiency and clinical excellence are already embedded in pricing, leaving limited room for upside if execution merely meets expectations. The 3Q26 discussion also showed uncertainty around reaching a 3.0% margin, with management not validating that Stars drives roughly two-thirds of the gap, while stronger-than-expected AEP could create only marginal headwind if pricing assumed fewer Year 1 members and gross member adds are still expected to decline year over year. More broadly, over 95% of revenue comes from government sources, exposing Humana to policy and reimbursement changes, while margin volatility, healthcare cost mispricing, and inflation at CenterWell threaten pressure on its long-term ~HSD% margin target and earnings multiple.